Abiomed Inc. (NASDAQ:ABMD) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $116.25 and last traded at $115.79, with a volume of 406,751 shares traded. The stock had previously closed at $114.15.

Several equities research analysts recently issued reports on the company. Jefferies Group reiterated a “buy” rating and set a $125.00 price target on shares of Abiomed in a report on Friday, June 10th. Leerink Swann restated a “buy” rating on shares of Abiomed in a research note on Friday, April 8th. Zacks Investment Research upgraded Abiomed from a “hold” rating to a “strong-buy” rating and set a $127.00 price objective for the company in a research note on Tuesday, July 5th. Finally, Benchmark Co. restated a “buy” rating and issued a $145.00 price objective on shares of Abiomed in a research note on Sunday, April 10th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $111.98.

The firm has a 50-day moving average of $104.48 and a 200-day moving average of $93.19. The stock has a market capitalization of $5.00 billion and a P/E ratio of 138.54.

Abiomed (NASDAQ:ABMD) last released its earnings results on Tuesday, May 3rd. The company reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.05. During the same quarter in the previous year, the business earned $2.24 EPS. The firm earned $94 million during the quarter, compared to analysts’ expectations of $90.52 million. The company’s revenue for the quarter was up 39.1% compared to the same quarter last year. Analysts forecast that Abiomed Inc. will post $1.13 earnings per share for the current fiscal year.

In other Abiomed news, VP Michael G. Howley sold 10,000 shares of Abiomed stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $106.58, for a total transaction of $1,065,800.00. Following the completion of the transaction, the vice president now owns 65,558 shares in the company, valued at $6,987,171.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO David M. Weber sold 52,000 shares of Abiomed stock in a transaction on Thursday, May 5th. The shares were sold at an average price of $95.27, for a total value of $4,954,040.00. Following the transaction, the chief operating officer now owns 121,676 shares of the company’s stock, valued at approximately $11,592,072.52. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently made changes to their positions in the stock. Redwood Investments LLC boosted its position in shares of Abiomed by 19.1% in the fourth quarter. Redwood Investments LLC now owns 22,724 shares of the company’s stock worth $2,052,000 after buying an additional 3,639 shares during the last quarter. Stephens Inc. AR boosted its position in shares of Abiomed by 20.1% in the fourth quarter. Stephens Inc. AR now owns 23,375 shares of the company’s stock worth $2,110,000 after buying an additional 3,918 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Abiomed by 4.2% in the fourth quarter. First Trust Advisors LP now owns 31,747 shares of the company’s stock worth $2,866,000 after buying an additional 1,275 shares during the last quarter. IronBridge Capital Management LP bought a new position in shares of Abiomed during the fourth quarter worth about $2,904,000. Finally, Oxford Asset Management bought a new position in shares of Abiomed during the fourth quarter worth about $3,015,000.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.